Stories of Change
Lillia is transforming chronic condition management. With AI precision and human empathy, we empower people to take control of their health, one micro-change at a time.
.png)
Significant blood sugar reduction
85% of high-risk users saw significant reduction in blood sugar
(↓ HbA1c by 2.5%)
Sustained weight loss
80% of users lost 5% of body weight
20% of users lost 10% of body weight
(↓ BMI by 1.3)
Reduced dependence on medication
35% of users reduced medication dependence in 3 months
Lives Transformed
Mr. Ar*****: Reversing diabetes naturally
"From HbA1c 12.6% to 5.7% in 3 months!"
Struggling with uncontrolled diabetes, weight gain, and chronic pain, Mr. Ar***** turned his life around with Lillia’s tech-powered solutions like continuous glucose monitoring. He shed 9 kg and resolved lethargy and skin allergies, proving the power of personalized, non-invasive care.
Client Speak
We are thrilled to collaborate with Lillia in our mission to lower diabetes rates and reduce healthcare costs for over 15,000 QLM members managing the condition. As we advance toward our vision of transforming healthcare from ‘Illness to Wellness,’ we eagerly anticipate the innovative AI-driven health solutions and systems they are developing.
Mohammed Salem,
Chief Business Officer,
QLM Life and Medical Insurance
Lillia in Focus
News, research, and thought leadership at the
intersection of AI and chronic care.
.png)
Lillia secures $1.7M grant to advance AI-powered chronic care
.png)
Lillia unveils its AI platform and digital twin technology to transform chronic disease management
Backed by a $1.7M QRDI Council grant and partnerships with 20 institutional clients, Lillia has already supported over 40,000 individuals across GCC and India, paving the way for global expansion and precision, AI-driven care
PHCC, Qatar: Largest diabetes management study in GCC
​
Published by American Diabetes Association (ADA) cohort of 633 patients across 27 Primary Health Care Corporation (PHCC) clinics
Outcome highlights
-
Reduction in HbA1c:
0.91% reduction for patients with initial HbA1c ≥ 8 -
Reduction in blood pressure:
7.84% reduction in systolic blood pressure for patients with initial BP ≥ 130/80 -
Reduction in cholesterol:
0.81 mmol/L reduction in total cholesterol for patients with cholesterol levels ≥ 5.18 mmol/L -
Reduction in weight:
0.72% reduction in BMI for patients with initial BMI ≥ 25
India: Large-scale diabetes management study
​
Published by American Diabetes Association (ADA) cohort of 808 patients across 50 cities in India
Outcome highlights
-
Reduction in HbA1c:
1.10% reduction for 808 patients
​
-
Reduction in HbA1c (uncontrolled
diabetes):
2.18% reduction for patients with
initial HbA1c ≥ 9
​
-
Increase in time in range (TIR):
7.16% increase for patients with
initial TIR of 40.3% ± 31%
Case Study: Leading clinic chain in India
​
Obesity and Diabetes Management Program
Outcome highlights
-
Reduction in HbA1c:
1.40% average reduction
​
-
Reduction in BMI:
3.35 average reduction for most compliant users
​
-
Reduction in weight:
3.50kg average reduction
Media Features
.png){kind=small}
